Form 4: MapLight CSO Awarded Equity, Options

MapLight Therapeutics' Chief Scientific Officer, James Woodruff Lillie, received 32,539 restricted stock units and options for 132,023 shares.

Summary

• James Woodruff Lillie, Chief Scientific Officer of MapLight Therapeutics, Inc. (MPLT), acquired 32,539 shares of Voting Common Stock in the form of Restricted Stock Units (RSUs) on October 27, 2025.
• Each RSU represents a contingent right to receive one share of voting common stock, with a transaction price of $0.
• The RSUs will vest with 1/4th on October 1, 2026, and 1/16th on each subsequent January 1, April 1, July 1, and October 1, subject to continued service.
• Additionally, Mr. Lillie acquired Employee Stock Options for 132,023 shares of Voting Common Stock on October 27, 2025, with an exercise price of $17 per share.
• These options have an expiration date of October 26, 2035.
• The options will vest with 1/4th of the total shares on October 1, 2026, and 1/48th of the total shares each month thereafter, subject to continued service.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.
• 侬],
• positives": [ "The grant of restricted stock units and stock options aligns the Chief Scientific Officer's long-term interests with those of the shareholders, incentivizing sustained performance.
• Equity compensation is a key tool for retaining valuable executive talent, particularly in the competitive biotechnology sector.
• The Rule 10b5-1 plan indicates a pre-arranged transaction, which can reduce concerns about opportunistic insider trading.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive like the Chief Scientific Officer is generally a positive signal for executive retention and alignment of interests with long-term shareholder value, reflecting confidence in the company's future.

Negatives

• The issuance of new equity awards, while standard, can lead to minor dilution for existing shareholders upon vesting and exercise.
• These awards do not represent an immediate cash infusion for the company.

Risks

• The vesting of both the restricted stock units and employee stock options is contingent upon the Chief Scientific Officer's continued service to MapLight Therapeutics, Inc.

Future Outlook

The equity awards are structured with future vesting schedules, aligning the Chief Scientific Officer's long-term incentives with the company's performance and continued service.

Industry Context

Equity compensation, particularly through RSUs and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key scientific and executive talent, aligning their interests with long-term shareholder value creation.

Comparison to Industry Standards

• The use of restricted stock units and employee stock options with multi-year vesting schedules is a common compensation structure for Chief Scientific Officers in early to mid-stage biotechnology companies, comparable to practices at peers like Moderna or BioNTech in their growth phases, aiming to retain talent and incentivize long-term value creation.

Stakeholder Impact

• Shareholders: Potential for minor dilution from future share issuance upon vesting/exercise, but also improved alignment of executive incentives with long-term company performance.
• Employees: Standard executive compensation package, potentially setting a precedent for other key personnel.
• Management: Strengthens retention and motivation of the Chief Scientific Officer.

Next Steps

• Continued service by the Chief Scientific Officer is required for the vesting of the granted restricted stock units and employee stock options.

Key Dates

Recommendation

The filing reports a significant equity grant to the Chief Scientific Officer, aligning his interests with long-term shareholder value through restricted stock units and stock options with multi-year vesting. While this is a positive for executive retention and incentivization, it is an insider transaction report and not a direct indicator of operational performance or financial results that would typically drive a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive signal without overstating its immediate impact on fundamental valuation.

Keywords

MapLight Therapeutics, MPLT, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, James Woodruff Lillie, Chief Scientific Officer, Equity Grant, Vesting